Literature DB >> 18794140

Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo.

Maryam Ahmadi1, David C Emery, David J Morgan.   

Abstract

Defects in antitumor immune responses have been associated with increased release of prostaglandin E(2) (PGE(2)) as a result of overexpression of cyclooxygenase (COX)-2 by tumors. In this report, we examine the effects of PGE(2) on antitumor CD8(+) T-cell responses generated both by cross-presenting dendritic cells and by direct priming by tumor cells. Our data show that PGE(2) inhibits dendritic cell maturation, resulting in the abortive activation of naive CD8(+) T cells, and is dependent on interleukin-10 production by dendritic cells. Interaction of tumor cells with naïve CD8(+) T cells in the presence of PGE(2) in vitro results in the induction of CD8(+) CD28(-) T cells, which fail to proliferate or exhibit effector function. In vivo, overexpression of COX-2 by tumor cells results in a decrease in number of tumor-infiltrating dendritic cells and confers the ability of tumor cells to metastasize to the tumor draining lymph nodes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18794140      PMCID: PMC2546514          DOI: 10.1158/0008-5472.CAN-08-1060

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

1.  Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance.

Authors:  Hans Christian Probst; Jacques Lagnel; George Kollias; Maries van den Broek
Journal:  Immunity       Date:  2003-05       Impact factor: 31.745

Review 2.  Immature, but not inactive: the tolerogenic function of immature dendritic cells.

Authors:  Karsten Mahnke; Edgar Schmitt; Laura Bonifaz; Alexander H Enk; Helmut Jonuleit
Journal:  Immunol Cell Biol       Date:  2002-10       Impact factor: 5.126

3.  A murine renal cell carcinoma.

Authors:  G P Murphy; W J Hrushesky
Journal:  J Natl Cancer Inst       Date:  1973-04       Impact factor: 13.506

4.  Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance.

Authors:  A H Enk; V L Angeloni; M C Udey; S I Katz
Journal:  J Immunol       Date:  1993-09-01       Impact factor: 5.422

5.  Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts.

Authors:  D I Gabrilovich; I F Ciernik; D P Carbone
Journal:  Cell Immunol       Date:  1996-05-25       Impact factor: 4.868

6.  Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor.

Authors:  Li Yang; Noboru Yamagata; Rajwardhan Yadav; Suzanne Brandon; Regina L Courtney; Jason D Morrow; Yu Shyr; Mark Boothby; Sebastian Joyce; David P Carbone; Richard M Breyer
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

7.  Renal cell carcinoma induces prostaglandin E2 and T-helper type 2 cytokine production in peripheral blood mononuclear cells.

Authors:  Gordon P Smyth; Philip P Stapleton; Catherine B Barden; Juan R Mestre; Tracy A Freeman; Michael D Duff; Sirish Maddali; Zhaoping Yan; John M Daly
Journal:  Ann Surg Oncol       Date:  2003-05       Impact factor: 5.344

8.  Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma.

Authors:  Yasuharu Akasaki; Gentao Liu; Nancy H C Chung; Moneeb Ehtesham; Keith L Black; John S Yu
Journal:  J Immunol       Date:  2004-10-01       Impact factor: 5.422

9.  IL-10 alters DC function via modulation of cell surface molecules resulting in impaired T-cell responses.

Authors:  Jacqueline M McBride; Thomas Jung; Jan E de Vries; Gregorio Aversa
Journal:  Cell Immunol       Date:  2002-02       Impact factor: 4.868

10.  Enhancement of colon carcinogenesis by prostaglandin E2 administration.

Authors:  Toshihiko Kawamori; Naoaki Uchiya; Takashi Sugimura; Keiji Wakabayashi
Journal:  Carcinogenesis       Date:  2003-05       Impact factor: 4.944

View more
  38 in total

1.  A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapy.

Authors:  Brynn B Duncan; Steven L Highfill; Haiying Qin; Najat Bouchkouj; Shannon Larabee; Peng Zhao; Iwona Woznica; Yuxin Liu; Youhua Li; Wengen Wu; Jack H Lai; Barry Jones; Crystal L Mackall; William W Bachovchin; Terry J Fry
Journal:  J Immunother       Date:  2013-10       Impact factor: 4.456

Review 2.  Role of prostanoids in gastrointestinal cancer.

Authors:  Dingzhi Wang; Raymond N DuBois
Journal:  J Clin Invest       Date:  2018-05-07       Impact factor: 14.808

Review 3.  The role of dendritic cells in cancer.

Authors:  Morten Hansen; Mads Hald Andersen
Journal:  Semin Immunopathol       Date:  2016-09-16       Impact factor: 9.623

4.  Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics.

Authors:  Maryam Ahmadi; Christine J Bryson; Edward A Cloake; Katie Welch; Vasco Filipe; Stefan Romeijn; Andrea Hawe; Wim Jiskoot; Matthew P Baker; Mark H Fogg
Journal:  Pharm Res       Date:  2015-04       Impact factor: 4.200

Review 5.  Inflammasomes and adaptive immune responses.

Authors:  Katherine A Deets; Russell E Vance
Journal:  Nat Immunol       Date:  2021-02-18       Impact factor: 25.606

6.  The parallel lives of angiogenesis and immunosuppression: cancer and other tales.

Authors:  Gregory T Motz; George Coukos
Journal:  Nat Rev Immunol       Date:  2011-09-23       Impact factor: 53.106

Review 7.  Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer.

Authors:  Taylor T Chrisikos; Yifan Zhou; Natalie Slone; Rachel Babcock; Stephanie S Watowich; Haiyan S Li
Journal:  Mol Immunol       Date:  2018-03-15       Impact factor: 4.407

8.  Pancreatic adenocarcinoma exerts systemic effects on the peripheral blood myeloid and plasmacytoid dendritic cells: an indicator of disease severity?

Authors:  Vegard Tjomsland; Per Sandström; Anna Spångeus; Davorka Messmer; Johan Emilsson; Ursula Falkmer; Sture Falkmer; Karl-Eric Magnusson; Kurt Borch; Marie Larsson
Journal:  BMC Cancer       Date:  2010-03-09       Impact factor: 4.430

9.  Chronic inhibition of cyclooxygenase-2 attenuates antibody responses against vaccinia infection.

Authors:  Matthew P Bernard; Simona Bancos; Timothy J Chapman; Elizabeth P Ryan; John J Treanor; Robert C Rose; David J Topham; Richard P Phipps
Journal:  Vaccine       Date:  2009-11-24       Impact factor: 3.641

10.  Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.

Authors:  Katy Milne; Martin Köbel; Steven E Kalloger; Rebecca O Barnes; Dongxia Gao; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.